Have a personal or library account? Click to login
A glance on recent progresses in diagnosis and treatment of primary immunodeficiencies/ Progrese recente în diagnosticul şi tratamentul imunodeficienţelor primare Cover

A glance on recent progresses in diagnosis and treatment of primary immunodeficiencies/ Progrese recente în diagnosticul şi tratamentul imunodeficienţelor primare

Revista Romana de Medicina de Laborator
Volume 22 (2014): Issue 3 (September 2014)
By: Peter J. Späth  
Open Access
|Oct 2014

References

  1. 1. Casanova JL, Abel L. The genetic theory of infectious diseases: A brief history and selected illustrations. Annu Rev Genomics Hum Genet. 2013;14:215-43. DOI: 10.1146/annurev-genom-091212-15344810.1146/annurev-genom-091212-153448498076123724903
    Search in Google Scholar
  2. 2. Pandolfi F, Milito C, Conti V, Pagliari D, Frosali S, Cianci R, et al. Common variable immunodeficiency - New insight into the pathogenesis and the quest for a workable classification. J Biol Regul Homeost Agents. 2013;27(2):285-9.
    Search in Google Scholar
  3. 3. Maggina P, Gennery AR. Classification of primary immunodeficiencies: need for a revised approach? J Allergy Clin Immunol. 2013 Feb;131(2):292-4. DOI: 10.1016/j.jaci.2012.10.00810.1016/j.jaci.2012.10.00823174660
    Search in Google Scholar
  4. 4. Al-Herz W, Bousfiha A, Casanova J-L, Chatila T, Conley ME, Cunningham-Rundles C, et al. Primary immunodeficiency diseases: An update on the classification from the International Union of immunological societies expert committee for primary immunodeficiency. Front Immunol. 2014;5(APR). DOI: 10.3389/ fimmu.2014.0016210.3389/fimmu.2014.00460
    Search in Google Scholar
  5. 5. Chinen J, Notarangelo LD, Shearer WT. Advances in basic and clinical immunology in 2013. J Allergy Clin Immunol. 2014 Feb 28;133(4):967-76. DOI: 10.1016/j. jaci.2014.01.026
    Search in Google Scholar
  6. 6. Hernandez-Trujillo V. New genetic discoveries and primary immune deficiencies. Clin Rev Allergy Immunol. 2014;46(2):145-53. DOI: 10.1007/s12016-013-8380-010.1007/s12016-013-8380-023860595
    Search in Google Scholar
  7. 7. Gathmann B, Binder N, Ehl S, Kindle G. The European internet-based patient and research database for primary immunodeficiencies: Update 2011. Clin Exp Immunol. 2012;167(3):479-91. DOI: 10.1111/j.1365-2249.2011.04542.x10.1111/j.1365-2249.2011.04542.x337428022288591
    Search in Google Scholar
  8. 8. Bousfiha AA, Jeddane L, Ailal F, Benhsaien I, Mahlaoui N, Casanova JL, et al. Primary immunodeficiency diseases worldwide: more common than generally thought. J Clin Immunol. 2013 Jan;33(1):1-7. DOI: 10.1007/s10875-012-9751-710.1007/s10875-012-9751-722847546
    Search in Google Scholar
  9. 9. Chapel H, Lucas M, Lee M, Björkander J, Webster D, Grimbacher B, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008 Jul 15;112(2):277-86. DOI: 10.1182/blood-2007-11-12454510.1182/blood-2007-11-12454518319398
    Search in Google Scholar
  10. 10. Wehr C, Kivioja T, Schmitt C, Ferry B, Witte T, Eren E, et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood. 2008 Jan 1;111(1):77-85. DOI: 10.1182/blood-2007-06-09174410.1182/blood-2007-06-09174417898316
    Search in Google Scholar
  11. 11. Baldovino S, Montin D, Martino S, Sciascia S, Menegatti E, Roccatello D. Common variable immunodeficiency: crossroads between infections, inflammation and autoimmunity. Autoimmun Rev. 2013 Jun;12(8):796-801. DOI: 10.1016/j.autrev.2012.11.00310.1016/j.autrev.2012.11.00323219764
    Search in Google Scholar
  12. 12. Gathmann B, Mahlaoui N, Gerard L, Oksenhendler E, Warnatz K, Schulze I, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol. 2014 Feb 27;Epub ahead of print. DOI: 10.1016/j.jaci.2013.12.107710.1016/j.jaci.2013.12.107724582312
    Search in Google Scholar
  13. 13. Eibel H, Salzer U, Warnatz K. Common variable immunodeficiency at the end of a prospering decade: Towards novel gene defects and beyond. Curr Opin Allergy Clin Immunol. 2010;10(6):526-33. DOI: 10.1097/ ACI.0b013e32833fea1c10.1097/ACI.0b013e32833fea1c
    Search in Google Scholar
  14. 14. Keller MD, Jyonouchi S. Chipping away at a mountain: Genomic studies in common variable immunodeficiency. Autoimmun Rev. 2013;12(6):687-9. DOI: 10.1016/j.autrev.2012.10.01710.1016/j.autrev.2012.10.017
    Search in Google Scholar
  15. 15. Todoric K, Koontz JB, Mattox D, Tarrant TK. Autoimmunity in immunodeficiency. Curr Allergy Asthma Rep. 2013;13(4):361-70. DOI: 10.1007/s11882-013-0350-310.1007/s11882-013-0350-3
    Search in Google Scholar
  16. 16. Bousfiha AA, Jeddane L, Ailal F, Al HW, Conley ME, Cunningham-Rundles C, et al. A phenotypic approach for IUIS PID classification and diagnosis: guidelines for clinicians at the bedside. J Clin Immunol. 2013 Aug;33(6):1078-87. DOI: 10.1007/s10875-013-9901-610.1007/s10875-013-9901-6
    Search in Google Scholar
  17. 17. Modell V, Gee B, Lewis DB, Orange JS, Roifman CM, Routes JM, et al. Global study of primary immunodeficiency diseases (PI)-diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunol Res. 2011 Oct;51(1):61-70. DOI: 10.1007/s12026-011-8241-y10.1007/s12026-011-8241-y
    Search in Google Scholar
  18. 18. Routes J, Abinun M, Al-Herz W, Bustamante J, Condino- Neto A, de la Morena MT, et al. ICON: The early diagnosis of congenital immunodeficiencies. J Clin Immunol. 2014 May;34(4):398-424. DOI: 10.1007/ s10875-014-0003-x10.1007/s10875-014-0003-x
    Search in Google Scholar
  19. 19. Modell F, Puente D, Modell V. From genotype to phenotype. Further studies measuring the impact of a Physician Education and Public Awareness Campaign on early diagnosis and management of Primary Immunodeficiencies. Immunol Res. 2009;44(1-3):132-49. DOI: 10.1007/s12026-008-8092-310.1007/s12026-008-8092-3
    Search in Google Scholar
  20. 20. Borte S, Borte M. Decreasing time-to-diagnosis in primary antibody deficiencies - The case for newborn screening programmes and awareness campaigns. Eur Infect Dis. 2012;6(2):99-104.
    Search in Google Scholar
  21. 21. MacGinnitie A, Aloi F, Mishra S. Clinical characteristics of pediatric patients evaluated for primary immunodeficiency. Pediatr Allergy Immunol. 2011;22(7):671-5. DOI: 10.1111/j.1399-3038.2011.01167.x10.1111/j.1399-3038.2011.01167.x
    Search in Google Scholar
  22. 22. Motamed F, Aghamohammadi A, Soltani M, Mansouri M, Rezaei N, Teimourian S, et al. Evaluation of liver diseases in Iranian patients with primary antibody deficiencies. Ann Hepatol. 2009 Jul;8(3):196-202.10.1016/S1665-2681(19)31765-X
    Search in Google Scholar
  23. 23. Dehkordy SF, Aghamohammadi A, Ochs HD, Rezaei N. Primary immunodeficiency diseases associated with neurologic manifestations. J Clin Immunol. 2012;32(1):1-24. DOI: 10.1007/s10875-011-9593-810.1007/s10875-011-9593-822038677
    Search in Google Scholar
  24. 24. Agarwal S, Mayer L. Diagnosis and treatment of gastrointestinal disorders in patients with primary immunodeficiency. Clin Gastroenterol Hepatol. 2013;11(9):1050-63. DOI: 10.1016/j.cgh.2013.02.02410.1016/j.cgh.2013.02.024380020423501398
    Search in Google Scholar
  25. 25. Hosseinverdi S, Hashemi H, Aghamohammadi A, Ochs HD, Rezaei N. Ocular involvement in primary immunodeficiency diseases. J Clin Immunol. 2014;34(1):23-38. DOI: 10.1007/s10875-013-9974-210.1007/s10875-013-9974-224292697
    Search in Google Scholar
  26. 26. Lehman H. Skin manifestations of primary immune deficiency. Clin Rev Allergy Immunol. 2014;46(2):112-9. DOI: 10.1007/s12016-013-8377-810.1007/s12016-013-8377-823760761
    Search in Google Scholar
  27. 27. Wood P. Primary antibody deficiencies: Recognition, clinical diagnosis and referral of patients. Clin Med (Lond Engl). 2009;9(6):595-9. DOI: 10.7861/clinmedicine. 9-6-595
    Search in Google Scholar
  28. 28. Abraham RS. Relevance of laboratory testing for the diagnosis of primary immunodeficiencies: A review of case-based examples of selected immunodeficiencies. Clin Mol Allergy. 2011;9:6. DOI: 10.1186/1476-7961-9-610.1186/1476-7961-9-6308080721477322
    Search in Google Scholar
  29. 29. de Vries E, European Society for Immunodeficiencies (ESID) members. Patient-centred screening for primary immunodeficiency, a multi-stage diagnostic protocol designed for non-immunologists: 2011 update. Clin Exp Immunol. 2012 Jan;167(1):108-19. DOI: 10.1111/j.1365-2249.2011.04461.x10.1111/j.1365-2249.2011.04461.x324809222132890
    Search in Google Scholar
  30. 30. Locke BA, Dasu T, Verbsky JW. Laboratory diagnosis of primary immunodeficiencies. Clin Rev Allergy Immunol. 2014 Apr;46(2):154-68. DOI: 10.1007/s12016-014-8412-410.1007/s12016-014-8412-424569953
    Search in Google Scholar
  31. 31. Borte S, Von Dobeln U, Hammarström L. Guidelines for newborn screening of primary immunodeficiency diseases. Curr Opin Hematol. 2013;20(1):48-54. DOI: 10.1097/MOH.0b013e32835a913010.1097/MOH.0b013e32835a913023108220
    Search in Google Scholar
  32. 32. Shearer WT, Dunn E, Notarangelo LD, Dvorak CC, Puck JM, Logan BR, et al. Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: The Primary Immune Deficiency Treatment Consortium experience. J Allergy Clin Immunol. 2014;133(4):1092-8. DOI: 10.1016/j.jaci.2013.09.04410.1016/j.jaci.2013.09.044397226624290292
    Search in Google Scholar
  33. 33. Chan K, Puck JM. Development of population-based newborn screening for severe combined immunodeficiency. J Allergy Clin Immunol. 2005 Feb;115(2):391-8. DOI: 10.1016/j.jaci.2004.10.01210.1016/j.jaci.2004.10.01215696101
    Search in Google Scholar
  34. 34. Janik DK, Lindau-Shepard B, Comeau AM, Pass KA. A multiplex immunoassay using the Guthrie specimen to detect T-cell deficiencies including severe combined immunodeficiency disease. Clin Chem. 2010 Sep;56(9):1460-5. DOI: 10.1373/ clinchem.2010.14432910.1373/clinchem.2010.144329322018320660143
    Search in Google Scholar
  35. 35. Borte S, Von Döbeln U, Fasth A, Wang N, Janzi M, Winiarski J, et al. Neonatal screening for severe prima ry immunodeficiency diseases using high-throughput triplex real-time PCR. Blood. 2012;119(11):2552-5. DOI: 10.1182/blood-2011-08-37102110.1182/blood-2011-08-37102122130802
    Search in Google Scholar
  36. 36. Chiarini M, Zanotti C, Serana F, Sottini A, Bertoli D, Caimi L, et al. T-cell receptor and K-deleting recombination excision circles in newborn screening of Tand B-cell defects: Review of the literature and future challenges. J Public Health Res. 2013;2(1):9-16. DOI: 10.4081/jphr.2013.e310.4081/jphr.2013.e3414032225170474
    Search in Google Scholar
  37. 37. Serana F, Chiarini M, Zanotti C, Sottini A, Bertoli D, Bosio A, et al. Use of V(D)J recombination excision circles to identify T- and B-cell defects and to monitor the treatment in primary and acquired immunodeficiencies. J Transl Med. 2013;11:119. DOI: 10.1186/1479-5876-11-11910.1186/1479-5876-11-119366688923656963
    Search in Google Scholar
  38. 38. la Marca G. Mass spectrometry in clinical chemistry: the case of newborn screening. J Pharm Biomed Anal. 2014 Apr 28;E pub ahead of print. DOI: 10.1016/j. jpba.2014.03.047
    Search in Google Scholar
  39. 39. Ameratunga R, Woon ST, Gillis D, Koopmans W, Steele R. New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin. Clin Exp Immunol. 2013;174(2):203-11. DOI: 10.1111/cei.1217810.1111/cei.12178382882323859429
    Search in Google Scholar
  40. 40. Seppänen M, Aghamohammadi A, Rezaei N. Is there a need to redefine the diagnostic criteria for common variable immunodeficiency? Expert Rev Clin Immunol. 2014;10(1):1-5. DOI: 10.1586/1744666X.2014.87047810.1586/1744666X.2014.87047824325452
    Search in Google Scholar
  41. 41. Nijman IJ, Van Montfrans JM, Hoogstraat M, Boes ML, Van De Corp, Renner ED, et al. Targeted next-generation sequencing: A novel diagnostic tool for primary immunodeficiencies. J Allergy Clin Immunol. 2014;133(2):529-34. DOI: 10.1016/j.jaci.2013.08.03210.1016/j.jaci.2013.08.03224139496
    Search in Google Scholar
  42. 42. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006 Aug 25;126(4):663-76. DOI: 10.1016/j.cell.2006.07.02410.1016/j.cell.2006.07.02416904174
    Search in Google Scholar
  43. 43. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007 Nov 30;131(5):861-72. DOI: 10.1016/j. cell.2007.11.019
    Search in Google Scholar
  44. 44. Pessach IM, Ordovas-Montanes J, Zhang SY, Casanova JL, Giliani S, Gennery AR, et al. Induced pluripotent stem cells: A novel frontier in the study of human primary immunodeficiencies. J Allergy Clin Immunol. 2011;127(6):1400-7. DOI: 10.1016/j.jaci.2010.11.00810.1016/j.jaci.2010.11.008308199321185069
    Search in Google Scholar
  45. 45. Hernandez-Trujillo HS, Chapel H, Lo RI, V, Notarangelo LD, Gathmann B, Grimbacher B, et al. Comparison of American and European practices in the management of patients with primary immunodeficiencies. Clin Exp Immunol. 2012 Jul;169(1):57-69. DOI: 10.1111/j.1365-2249.2012.04588.x10.1111/j.1365-2249.2012.04588.x339047422670779
    Search in Google Scholar
  46. 46. Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, et al. Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006 Apr;117(4 Suppl): S525-S553. DOI: 10.1016/j.jaci.2006.01.01510.1016/j.jaci.2006.01.01516580469
    Search in Google Scholar
  47. 47. Stonebraker JS, Farrugia A, Gathmann B, ESID Registry Woking Party, Orange JS. Modeling primary immunodeficiency disease epidemiology and its treatment to estimate latent therapeutic demand for immunoglobulin. J Clin Immunol. 2014 Feb;34(2):233-44. DOI: 10.1007/s10875-013-9975-110.1007/s10875-013-9975-124338563
    Search in Google Scholar
  48. 48. Robinson P, Anderson D, Brouwers M, Feasby TE, Hume H. Evidence-based guidelines on the use of intravenous immune globulin for hematologic and neurologic conditions. Transfus Med Rev. 2007 Apr;21(2 Suppl 1):S3-S8. DOI: 10.1016/j.tmrv.2007.01.00410.1016/j.tmrv.2007.01.00417397767
    Search in Google Scholar
  49. 49. Shehata N, Palda V, Bowen T, Haddad E, Issekutz TB, Mazer B, et al. The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline. Transfus Med Rev. 2010 Jan;24(Suppl. 1):S28-S50. DOI: 10.1016/j. tmrv.2009.09.011
    Search in Google Scholar
  50. 50. Sewell WC, Kerr J, Behr-Gross ME, Peter HH. European consensus proposal for immunoglobulin therapies. Eur J Immunol. 2014 Jun 28. DOI: 10.1002/ eji.201444700
    Search in Google Scholar
  51. 51. Beauté J, Levy P, Millet V, Debré M, Dudoit Y, Le Mignot L, et al. Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies. Clin Exp Immunol. 2010;160(2):240-5. DOI: 10.1111/j.1365-2249.2009.04079.x10.1111/j.1365-2249.2009.04079.x285794720041884
    Search in Google Scholar
  52. 52. Lingman-Framme J, Fasth A. Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: An evidence-based review. Drugs. 2013;73(12):1307-19. DOI: 10.1007/s40265-013-0094-310.1007/s40265-013-0094-323861187
    Search in Google Scholar
  53. 53. Torgerson TR, Bonagura VR, Shapiro RS. Clinical ambiguities - Ongoing questions. J Clin Immunol. 2013;33(2 SUPPL.):S99-S103. DOI: 10.1007/s10875-012-9851-410.1007/s10875-012-9851-423242829
    Search in Google Scholar
  54. 54. Martin A, Lavoie L, Goetghebeur M, Schellenberg R. Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency. Transfus Med. 2013;23(1):55-60. DOI: 10.1111/j.1365-3148.2012.01201.x10.1111/j.1365-3148.2012.01201.x358087923167310
    Search in Google Scholar
  55. 55. Shapiro R. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. J Clin Immunol. 2010 Mar;30(2):301-7. DOI: 10.1007/s10875-009-9352-210.1007/s10875-009-9352-220082124
    Search in Google Scholar
  56. 56. Wasserman RL, Melamed I, Stein MR, Gupta S, Puck J, Engl W, et al. Recombinant human hyaluronidase-fa cilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol. 2012;130(4):951-7. DOI: 10.1016/j. jaci.2012.06.021
    Search in Google Scholar
  57. 57. Chapel H, Gardulf A. Subcutaneous immunoglobulin replacement therapy: The European experience. Curr Opin Allergy Clin Immunol. 2013;13(6):623-9. DOI: 10.1097/ACI.000000000000001310.1097/ACI.000000000000001324126615
    Search in Google Scholar
  58. 58. Espanol T, Prevot J, Drabwell J, Sondhi S, Olding L. Improving current immunoglobulin therapy for patients with primary immunodeficiency: Quality of life and views on treatment. Patient Preference Adherence. 2014;8:621-9. DOI: 10.2147/PPA.S6077110.2147/PPA.S60771401437724833896
    Search in Google Scholar
  59. 59. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin Immunol. 2010 Oct;137(1):21-30. DOI: 10.1016/j.clim.2010.06.01210.1016/j.clim.2010.06.01220675197
    Search in Google Scholar
  60. 60. Orange JS, Belohradsky BH, Berger M, Borte M, Hagan J, Jolles S, et al. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol. 2012 Aug;169(2):172-81. DOI: 10.1111/j.1365-2249.2012.04594.x10.1111/j.1365-2249.2012.04594.x340637722774992
    Search in Google Scholar
  61. 61. Oksenhendler E, Gérard L, Fieschi C, Malphettes M, Mouillot G, Jaussaud R, et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis. 2008;46(10):1547-54. DOI: 10.1086/58766910.1086/58766918419489
    Search in Google Scholar
  62. 62. Llobet MP, Soler-Palacin P, Detkova D, Hernandez M, Caragol I, Espanol T. Common variable immunodeficiency: 20-yr experience at a single centre. Pediatr Allergy Immunol. 2009 Mar;20(2):113-8. DOI: 10.1111/j.1399-3038.2008.00744.x10.1111/j.1399-3038.2008.00744.x18798799
    Search in Google Scholar
  63. 63. Quinti I, Soresina A, Guerra A, Rondelli R, Spadaro G, Agostini C, et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: Results from a multicenter prospective cohort study. J Clin Immunol. 2011;31(3):315-22. DOI: 10.1007/s10875-011-9511-010.1007/s10875-011-9511-021365217
    Search in Google Scholar
  64. 64. Gregersen S, Aaløkken TM, Mynarek G, Fevang B, Holm AM, Ueland T, et al. Development of pulmonary abnormalities in patients with common variable immunodeficiency: associations with clinical and immunologic factors. Annals of Allergy, Asthma and Immunology. 2010;104(6):503-10. DOI: 10.1016/j. anai.2010.04.015
    Search in Google Scholar
  65. 65. Gouilleux-Gruart V, Chapel H, Chevret S, Lucas M, Malphettes M, Fieschi C, et al. Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: Correlations with clinical phenotype and polymorphism of the neonatal Fc receptor. Clin Exp Immunol. 2013;171(2):186-94. DOI: 10.1111/ cei.1200210.1111/cei.12002357328923286945
    Search in Google Scholar
  66. 66. Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol. 2008 Jul;122(1):210-2. DOI: 10.1016/j.jaci.2008.04.04410.1016/j.jaci.2008.04.04418602574
    Search in Google Scholar
  67. 67. Berger M, Rojavin M, Kiessling P, Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol. 2011;139(2):133-41. DOI: 10.1016/j.clim.2011.01.00610.1016/j.clim.2011.01.00621353644
    Search in Google Scholar
  68. 68. Wasserman RL. Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again. J Clin Immunol. 2012;32(6):1153-64. DOI: 10.1007/s10875-012-9740-x10.1007/s10875-012-9740-x22828788
    Search in Google Scholar
  69. 69. Mouillot G, Carmagnat M, Gérard L, Garnier JL, Fieschi C, Vince N, et al. B-cell and T-cell phenotypes in CVID patients correlate with the clinical phenotype of the disease. J Clin Immunol. 2010;30(5):746-55. DOI: 10.1007/s10875-010-9424-310.1007/s10875-010-9424-320437084
    Search in Google Scholar
  70. 70. Resnick ES, Moshier EL, Godbold JH, Cunningham- Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 2012;119(7):1650-7. DOI: 10.1182/ blood-2011-09-37794510.1182/blood-2011-09-377945328634322180439
    Search in Google Scholar
  71. 71. Rapley P, Davidson PM. Enough of the problem: a review of time for health care transition solutions for young adults with a chronic illness. J Clin Nurs. 2010 Feb;19(3-4):313-23. DOI: 10.1111/j.1365-2702.2009.03027.x10.1111/j.1365-2702.2009.03027.x20500270
    Search in Google Scholar
  72. 72. Agarwal S, Cunningham-Rundles C. Treatment of hypogammaglobulinemia in adults: A scoring system to guide decisions on immunoglobulin replacement. J Allergy Clin Immunol. 2013;131(6):1699-701. DOI: 10.1016/j.jaci.2013.01.03610.1016/j.jaci.2013.01.036410231223518142
    Search in Google Scholar
  73. 73. O’Mahony B, Turner A. The Dublin Consensus Statement 2011 on vital issues relating to the collection and provision of blood components and plasma-derived medicinal products. Vox Sang. 2012 Feb;102(2):140-3. DOI: 10.1111/j.1423-0410.2011.01528.x10.1111/j.1423-0410.2011.01528.x21806632
    Search in Google Scholar
  74. 74. Späth PJ, Van Holten RW, Kempf C. Pathogen safety of immunoglobulin preparations. In: Wahn V, Orange J, editors. Clinical Use of Immunoglobulins. 2nd ed. Bremen - London - Boston: UNI-MED Verlag; 2013. p.26-50.
    Search in Google Scholar
  75. 75. Vassilev TL, Bineva IL, Dietrich G, Kaveri SV, Kazatchkine MD. Variable region-connected, dimeric fraction of intravenous immunoglobulin enriched in natural autoantibodies. J Autoimmun. 1995 Jun;8(3):405-13. DOI: 10.1006/jaut.1995.003210.1006/jaut.1995.00327576001
    Search in Google Scholar
  76. 76. Späth PJ, Lutz HU. Naturally occurring antibodies/ autoantibodies in polyclonal immunoglobulin concentrates. Lutz HU, editor. Naturally Occurring Antibodies (NAbs). Advances in Experimental Medicine and Biology[ 750], 239-261. 16-4-2012. Austin, TX USA, Lan des Bioscience and Springer Science+Business Media. Advances in Experimental Medicine and Biology.10.1007/978-1-4614-3461-0_1822903679
    Search in Google Scholar
  77. 77. Berger M. Adverse effects of IgG therapy. J Allergy Clin Immunol. Pract. 2013;1(6):558-66. DOI: 10.1016/j.jaip.2013.09.01210.1016/j.jaip.2013.09.01224565701
    Search in Google Scholar
  78. 78. Gürcan HM, Keskin DB, Ahmed AR. Information for healthcare providers on general features of IGIV with emphasis on differences between commercially available products. Autoimmun Rev. 2010;9(8):553-9. DOI: 10.1016/j.autrev.2010.03.00310.1016/j.autrev.2010.03.00320346419
    Search in Google Scholar
  79. 79. Etscheid M, Breitner-Ruddock S, Gross S, Hunfeld A, Seitz R, Dodt J. Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products. Vox Sang. 2012 Jan;102(1):40-6. DOI: 10.1111/j.1423-0410.2011.01502.x10.1111/j.1423-0410.2011.01502.x21545600
    Search in Google Scholar
  80. 80. Desborough MJ, Miller J, Thorpe SJ, Murphy MF, Misbah SA. Intravenous immunoglobulin-induced haemolysis: a case report and review of the literature. Transfus Med. 2013 Oct 25;E-pub ahead of print. DOI: 10.1111/ tme.12083
    Search in Google Scholar
  81. 81. Schroeder HW, Jr., Dougherty CJ. Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients. Infect. 2012;40(6):601-11. DOI: 10.1007/s15010-012-0323-910.1007/s15010-012-0323-9350119122968971
    Search in Google Scholar
  82. 82. Dhainaut F, Guillaumat PO, Dib H, Perret G, Sauger A, De Coupade C, et al. In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations. Vox Sang. 2013;104(2):115-26. DOI: 10.1111/j.1423-0410.2012.01648.x10.1111/j.1423-0410.2012.01648.x358088023003576
    Search in Google Scholar
  83. 83. Medical Advisory Committee of the Immune Deficiency Foundation, Shearer WT, Fleisher TA, Buckley RH, Ballas Z, Ballow M, et al. Recommendations for live viral and bacterial vaccines in immunodeficient patients and their close contacts. J Allergy Clin Immunol. 2014 Apr;133(4):961-6. DOI: 10.1016/j.jaci.2013.11.04310.1016/j.jaci.2013.11.043400934724582311
    Search in Google Scholar
  84. 84. Worth AJJ, Booth C, Veys P. Stem cell transplantation for primary immune deficiency. Curr Opin Hematol. 2013;20(6):501-8. DOI: 10.1097/MOH.0b013e-328365a13b
    Search in Google Scholar
  85. 85. Cavazzana-Calvo M, Andre-Schmutz I, Fischer A. Haematopoietic stem cell transplantation for SCID patients: Where do we stand? Br J Haematol. 2013;160(2):146-52. DOI: 10.1111/bjh.1211910.1111/bjh.12119
    Search in Google Scholar
  86. 86. Güngör T, Teira P, Slatter M, Stussi G, Stepensky P, Moshous D, et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet. 2014 Feb 1;383(9915):436-48. DOI: 10.1016/S0140-6736(13)62069-310.1016/S0140-6736(13)62069-3
    Search in Google Scholar
  87. 87. Lane JP, Evans PTG, Nademi Z, Barge D, Jackson A, Hambleton S, et al. Low-dose serotherapy improves early immune reconstitution after cord blood transplantation for primary immunodeficiencies. Biol Blood Marrow Transplant. 2014;20(2):243-9. DOI: 10.1016/j. bbmt.2013.11.005
    Search in Google Scholar
  88. 88. Zou J, Sweeney CL, Chou BK, Choi U, Pan J, Wang H, et al. Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood. 2011 May 26;117(21):5561-72. DOI: 10.1182/blood-2010-12-32816110.1182/blood-2010-12-328161311002121411759
    Search in Google Scholar
  89. 89. Cavazzana-Calvo M, Fischer A, Hacein-Bey-Abina S, Aiuti A. Gene therapy for primary immunodeficiencies: Part 1. Curr Opin Immunol 2012 Oct;24(5):580-4. DOI: 10.1016/j.coi.2012.08.00810.1016/j.coi.2012.08.00822981681
    Search in Google Scholar
  90. 90. Aiuti A, Bacchetta R, Seger R, Villa A, Cavazzana-Calvo M. Gene therapy for primary immunodeficiencies: Part 2. Curr Opin Immunol 2012 Oct;24(5):585-91. DOI: 10.1016/j.coi.2012.07.01210.1016/j.coi.2012.07.01222909900
    Search in Google Scholar
  91. 91. Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. Gene therapy of primary T cell immunodeficiencies. Gene. 2013;525(2):170-3. DOI: 10.1016/j. gene.2013.03.092
    Search in Google Scholar
  92. 92. Touzot F, Hacein-Bey-Abina S, Fischer A, Cavazzana M. Gene therapy for inherited immunodeficiency. Expert Opin Biol Ther. 2014 Jun;14(6):789-98. DOI: 10.1517/14712598.2014.89581110.1517/14712598.2014.89581124823313
    Search in Google Scholar
  93. 93. Farinelli G, Capo V, Scaramuzza S, Aiuti A. Lentiviral vectors for the treatment of primary immunodeficiencies. J Inherit Metab Dis. 2014 Mar 12;Epub ahead of print. DOI: 10.1007/s10545-014-9690-y10.1007/s10545-014-9690-y24619149
    Search in Google Scholar
  94. 94. Mukherjee S, Thrasher AJ. Gene therapy for PIDs: progress, pitfalls and prospects. Gene. 2013 Aug 10;525(2):174-81. DOI: 10.1016/j.gene.2013.03.098 10.1016/j.gene.2013.03.098372541723566838
    Search in Google Scholar
DOI: https://doi.org/10.2478/rrlm-2014-0034 | Journal eISSN: 2284-5623 | Journal ISSN: 1841-6624
Journal RSS Feed
Language: English
Page range: 297 - 309
Submitted on: Jul 6, 2014
|
Accepted on: Aug 25, 2014
|
Published on: Oct 8, 2014
Published by: Romanian Association of Laboratory Medicine
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Awareness,
early diagnosis,
gene therapy,
hematopoietic stem cell transplantation,
immunoglobulin G concentrates,
new-born screening,
primary immunodeficiencies,
replacement therapy
Related subjects:
Life sciences,
Molecular biology,
Biochemistry,
Human biology,
Microbiology and virology

© 2014 Peter J. Späth, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 22 (2014): Issue 3 (September 2014)Next article